Webinar: Optimised workflow for rapid identification of neutralising antibodies against viral particles
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
The timeline to identify and develop clinically effective neutralising antibodies against viral particles from bench to patient is 18 to 24 months. In this webinar, Molecular Devices scientists demonstrate the steps from clonal selection to cell growth tracking to image-based assurance of monoclonality and show how, using a combination of CloneSelect instruments and screening platforms, the timeline for preclinical development of effective neutralising antibodies can be significantly shortened.
Related content from this organisation
- Application note: Measure viral-induced cytopathic effects with a quantitative luminescence assay
- Application note: High-throughput IgG quantitation platform for clone screening during drug discovery and development
- ebook: Optimise your high value cell lines
- ebook: Accelerate vaccine development
- Video: Imaging and analysis of a 3D airway organoid model